Literature DB >> 29182383

Ovarian cancer: how can resistance to chemotherapy be tackled?

Sergey Karakashev1, Katherine M Aird2.   

Abstract

Entities:  

Keywords:  BET inhibitors; chemoresistance; immunotherapy; ovarian cancer

Mesh：

Substances：

Year:  2017        PMID： 29182383     DOI： 10.2217/fon-2017-0235

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  5 in total

1.  Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.

Authors:  Shipeng Gong; Yongning Chen; Fanliang Meng; Yadi Zhang; Chanyuan Li; Guangping Zhang; Wu Huan; Fei Wu
Journal:  Cell Prolif       Date:  2018-08-02       Impact factor: 6.831

2.  Cyclin H predicts the poor prognosis and promotes the proliferation of ovarian cancer.

Authors:  Chen Peng; Yansong Yang; Li Ji; Panpan Yang; Xiaoqing Yang; Yuquan Zhang
Journal:  Cancer Cell Int       Date:  2020-07-16       Impact factor: 5.722

3.  Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.

Authors:  Chencheng Dai; Pengfei Xu; Siyu Liu; Sujuan Xu; Juan Xu; Ziyi Fu; Jian Cao; Mingming Lv; Juan Zhou; Guangquan Liu; Huilin Zhang; Xuemei Jia
Journal:  Arch Gynecol Obstet       Date:  2020-11-05       Impact factor: 2.344

4.  ATP binding cassette subfamily B member 9 (ABCB9) is a prognostic indicator of overall survival in ovarian cancer.

Authors:  Lin Hou; Xueying Zhang; Yan Jiao; Yanqing Li; Yuechen Zhao; Yinuo Guan; Ziling Liu
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  Regulation of MYB mediated cisplatin resistance of ovarian cancer cells involves miR-21-wnt signaling axis.

Authors:  Xue-Yan Zhang; Yun-Feng Li; He Ma; Yun-He Gao
Journal:  Sci Rep       Date:  2020-04-23       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.